1. Home
  2. DTST vs ACXP Comparison

DTST vs ACXP Comparison

Compare DTST & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Data Storage Corporation

DTST

Data Storage Corporation

HOLD

Current Price

$3.33

Market Cap

7.7M

Sector

Technology

ML Signal

HOLD

Logo Acurx Pharmaceuticals Inc.

ACXP

Acurx Pharmaceuticals Inc.

HOLD

Current Price

$1.68

Market Cap

8.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DTST
ACXP
Founded
2001
2017
Country
United States
United States
Employees
7
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.7M
8.3M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
DTST
ACXP
Price
$3.33
$1.68
Analyst Decision
Hold
Strong Buy
Analyst Count
1
2
Target Price
N/A
$95.50
AVG Volume (30 Days)
37.8K
93.4K
Earning Date
04-14-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$25.39
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$2.31
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.25
$0.29
52 Week High
$5.44
$8.34

Technical Indicators

Market Signals
Indicator
DTST
ACXP
Relative Strength Index (RSI) 32.37 32.79
Support Level N/A $1.37
Resistance Level $4.47 $2.26
Average True Range (ATR) 0.21 0.14
MACD -0.05 0.01
Stochastic Oscillator 17.86 3.39

Price Performance

Historical Comparison
DTST
ACXP

About DTST Data Storage Corporation

Data Storage Corporation engages in providing cybersecurity, compliance and cloud computing solutions. The company's segment includes Nexxis Inc and corporate segment. It generates maximum revenue from the Nexxis Corporation segment. The company's solutions include infrastructure, disaster recovery, email archival, compliance, electronic vaulting, virtualized recovery, telecom recovery services, and continuous data protection.

About ACXP Acurx Pharmaceuticals Inc.

Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.

Share on Social Networks: